· Recommends dividend of Rs. 7 per equity share of Rs. 10 each (70%) for the financial year 2024-25
Ahmedabad, May 10, 2025: Hester Biosciences Limited, one of India’s leading animal health company, manufacturing vaccines and health products has reported consolidated net profit of Rs. 28.83 crore for the financial year ended March 2025, rise of 36% as compared to the net profit of Rs. 21.17 crore reported in the financial year 2023-24. Revenue from operations of the company for the FY25 was reported at Rs. 311.10 crore, rise of 2% Y-o-Y as compared to the revenue from operations of Rs. 304.55 crore. Company has recommended dividend of Rs. 7 (Seven) per equity share of Rs. 10 each (70%) for the financial year 2024-25, subject to the approval of members at the ensuing Annual General Meeting.
Standalone Performance: Divisional Product Sales in FY25 was up by 12% and in Q4 FY25 it was up by 5%. Net Profit in FY25 was up by 17% and in Q4 FY25 it was up by 30%
Consolidated Performance: Divisional Product Sales in FY25 was up by 13% and in Q4 FY25 it was up by 3%. Net Profit in FY25 up by 36% and in Q4 FY25 it was down by 76%
Way Forward
Looking ahead, Hester remains focused on deepening its presence across all core segments while maintaining strong operational discipline. The company is on track to launch the Avian Influenza vaccine and expand its portfolio of feed supplements and disinfectants in the Poultry Healthcare Division, creating new domestic and export opportunities.
In the Animal Division, efforts will be on broadening the nutritional and therapeutic product range to meet evolving market needs and strengthen market share. Continued investments in product development, supply chain efficiency, and customer engagement will drive sustainable growth.
Hester is also prioritising international expansion, with a strong focus on scaling its Africa operations and strengthening its presence in existing and new geographies, aligned with its long-term vision of global leadership in animal healthcare.
Consolidated results include operations of subsidiaries from Nepal and Tanzania:
1) Hester Nepal reported a net profit of INR1.20 crore for FY25, supported by fulfilling export orders from international tenders for the LSD vaccine and meeting domestic vaccine demand for poultry.
2) Hester Africa reduced its net loss to INR10.27 crore compared to INR18.30 crore in FY24, backed by stronger sales and tender wins for the supply of PPR and CBPP vaccines. The subsidiary also received marketing authorisation for a new live combination vaccine covering PPR and Sheep & Goat Pox — an important development for ruminant health.
Corporate Comm India (CCI Newswire)
